JP2000517299A - 癌細胞における２―メトキシエストラジオール誘導アポトーシス - Google Patents

癌細胞における２―メトキシエストラジオール誘導アポトーシス

Info

Publication number
JP2000517299A
JP2000517299A JP10508981A JP50898198A JP2000517299A JP 2000517299 A JP2000517299 A JP 2000517299A JP 10508981 A JP10508981 A JP 10508981A JP 50898198 A JP50898198 A JP 50898198A JP 2000517299 A JP2000517299 A JP 2000517299A
Authority
JP
Japan
Prior art keywords
cells
wild
meoe
cell
gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP10508981A
Other languages
English (en)
Japanese (ja)
Other versions
JP2000517299A5 (enExample
Inventor
ムクホパディアイ，タパス
エイ． ロス，ジャック
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
Original Assignee
University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System filed Critical University of Texas System
Publication of JP2000517299A publication Critical patent/JP2000517299A/ja
Publication of JP2000517299A5 publication Critical patent/JP2000517299A5/ja
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP10508981A 1996-07-30 1997-07-24 癌細胞における２―メトキシエストラジオール誘導アポトーシス Ceased JP2000517299A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/688,613 1996-07-30
US08/688,613 US5958892A (en) 1996-07-30 1996-07-30 2-methoxyestradiol-induced apoptosis in cancer cells
PCT/US1997/012998 WO1998004291A1 (en) 1996-07-30 1997-07-24 2-methoxyestradiol-induced apoptosis in cancer cells

Publications (2)

Publication Number Publication Date
JP2000517299A true JP2000517299A (ja) 2000-12-26
JP2000517299A5 JP2000517299A5 (enExample) 2005-04-07

Family

ID=24765087

Family Applications (1)

Application Number Title Priority Date Filing Date
JP10508981A Ceased JP2000517299A (ja) 1996-07-30 1997-07-24 癌細胞における２―メトキシエストラジオール誘導アポトーシス

Country Status (8)

Country Link
US (3) US5958892A (enExample)
EP (1) EP0921821B1 (enExample)
JP (1) JP2000517299A (enExample)
AT (1) ATE279212T1 (enExample)
AU (1) AU723401B2 (enExample)
CA (1) CA2262533A1 (enExample)
DE (1) DE69731213T2 (enExample)
WO (1) WO1998004291A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005530712A (ja) * 2002-03-20 2005-10-13 エラン ファーマ インターナショナル，リミティド 血管新生抑制剤のナノ粒子組成物

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5504074A (en) * 1993-08-06 1996-04-02 Children's Medical Center Corporation Estrogenic compounds as anti-angiogenic agents
US20040214807A1 (en) * 1993-08-06 2004-10-28 D'amato Robert J. Estrogenic compounds as anti-mitotic agents
US6346510B1 (en) 1995-10-23 2002-02-12 The Children's Medical Center Corporation Therapeutic antiangiogenic endostatin compositions
US20030064949A1 (en) * 1998-02-17 2003-04-03 Loretta Nielsen Combined tumor suppressor gene therapy and chemotherapy in the treatment of neoplasms
US20030060434A1 (en) * 1997-02-18 2003-03-27 Loretta Nielsen Combined tumor suppressor gene therapy and chemotherapy in the treatment of neoplasms
KR20010086073A (ko) * 1998-12-02 2001-09-07 데이비드 존 우드 ｐ53계 단백질의 배좌 안정성을 회복하기 위한 방법 및조성물
US6548541B1 (en) * 1999-04-21 2003-04-15 Unitech Pharmaceuticals, Inc. Carboplatin analogs for cancer treatment
US6730665B1 (en) 1999-05-12 2004-05-04 Mayo Foundation For Medical Education And Research Treatment of bone cancer
AU5010500A (en) * 1999-05-12 2000-11-21 Mayo Foundation For Medical Education And Research Treatment of bone cancer
US7087592B1 (en) * 1999-08-23 2006-08-08 Entre Med, Inc. Compositions comprising purified 2-methoxyestradiol and methods of producing same
US6518261B2 (en) * 2000-03-17 2003-02-11 Oncology Sciences Corporation Use of eugenol in combination with other chemopreventative agents as prophylaxis for cancers
US7135581B2 (en) * 2000-08-18 2006-11-14 Entremed, Inc. Antiangiogenic agents
US6995278B2 (en) * 2000-08-18 2006-02-07 Entre Med, Inc. Antiangiogenic agents
US20050192258A1 (en) * 2000-08-18 2005-09-01 Agoston Gregory E. Antiangiogenic agents
US7691567B2 (en) 2000-10-30 2010-04-06 Board Of Regents, The University Of Texas System Methods and compositions relating to fortilin, an anti-apoptotic molecule, and modulators of fortilin
WO2002062348A1 (en) * 2001-02-05 2002-08-15 Oncology Sciences Corporation Eugenol, optionally in combination with 2-methoxyestradiol, as a cancer chemopreventative agent
DE60213386T2 (de) * 2001-03-30 2006-11-23 The United States Of America Represented By The Secretary, Department Of Health And Human Services Geldanamycinderivate zur krebsbehandlung
US20030236439A1 (en) * 2002-01-30 2003-12-25 Gregory Agoston Non-steroidal analogs of 2-methoxyestradiol
WO2003073985A2 (en) * 2002-03-01 2003-09-12 Entremed, Inc. New methods of using antiangiogenic agents
BR0312664A (pt) 2002-07-18 2005-05-03 Helix Biopharma Corp Composição farmacêutica e uso da enzima urease para a fabricação de um medicamento para o tratamento de células cancerìgenas em um indivìduo
KR20050057086A (ko) 2002-08-28 2005-06-16 홀리스-에덴 파마슈티칼즈, 인코포레이티드 치료적 처치 방법
EP1587519A4 (en) * 2003-01-10 2006-05-31 Threshold Pharmaceuticals Inc Treatment of cancer with 2-deoxyglucose
US7160908B2 (en) * 2003-03-04 2007-01-09 Unitech Pharmaceuticals, Inc. Dynamic anticancer platinum compounds
WO2005030120A2 (en) * 2003-05-28 2005-04-07 Entremed, Inc. Antiangiogenic agents
US20070004689A1 (en) * 2004-03-12 2007-01-04 Agoston Gregory E Antiangiogenic agents
EP1756139A4 (en) 2004-03-12 2009-07-29 Entremed Inc ANTI-ANGIOGENIC AGENTS
KR20070057240A (ko) * 2004-09-13 2007-06-04 피알 파마슈티칼스, 인크. 장시간 작용하고 주사가능한 에스트라디올 대사산물의 결정제제 및 이를 사용하는 방법
EP1819343A2 (en) * 2004-11-29 2007-08-22 EntreMed, Inc. A method of administering anti-angiogenic agents and a method of treating disease using same
WO2007059111A2 (en) * 2005-11-14 2007-05-24 Entremed, Inc. Anti-angiogenic activity of 2-methoxyestradiol in combination with anti-cancer agents
US20070176403A1 (en) * 2006-02-01 2007-08-02 Dennis Calderone Air adjustable seat
WO2007097839A2 (en) * 2006-02-16 2007-08-30 Massachusetts Eye And Ear Infirmary Ansamycin analogs or heat shock 90 inhibitors in combination with pdt treatin conditions of the eye
CA2646065C (en) * 2006-03-20 2014-01-14 Entremed, Inc. Disease modifying anti-arthritic activity of 2-methoxyestradiol
WO2008094665A1 (en) * 2007-01-31 2008-08-07 Entremed, Inc. Method of treating amyloidosis mediated diseases
WO2008150550A1 (en) * 2007-06-05 2008-12-11 Cornell University Compounds for enhancing p21 expression and methods of use thereof
KR20090009637A (ko) * 2007-07-20 2009-01-23 삼성전자주식회사 엠비-오에프디엠 시스템 및 프레임 바운더리 검출 방법
MX388453B (es) * 2015-10-08 2025-03-20 Univ Utah Res Found Composiciones para usarse en el tratamiento de cáncer.
KR101837735B1 (ko) * 2016-08-08 2018-04-19 성균관대학교산학협력단 TCTP (Translationally controlled tumour protein) 단백질을 포함하는 난모세포(oocytes) 노화 방지 또는 수정능력 개선용 조성물

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5532220A (en) 1987-08-31 1996-07-02 The Regents Of The University Of California Genetic mechanisms of tumor suppression
EP0440744B1 (en) 1988-10-31 1997-12-10 The Regents Of The University Of California Products and methods for controlling the suppression of the neoplastic phenotype
US5527676A (en) 1989-03-29 1996-06-18 The Johns Hopkins University Detection of loss of the wild-type P53 gene and kits therefor
DE69032864T3 (de) 1989-03-29 2013-01-31 The Johns Hopkins University Nachweis des Ausfalls des Wildtyps des p53-Gens
IE911115A1 (en) 1990-04-10 1991-10-23 Canji Inc Gene therapy for cell proliferative diseases
US5747469A (en) * 1991-03-06 1998-05-05 Board Of Regents, The University Of Texas System Methods and compositions comprising DNA damaging agents and p53
US6410010B1 (en) * 1992-10-13 2002-06-25 Board Of Regents, The University Of Texas System Recombinant P53 adenovirus compositions
DK0648271T3 (da) 1991-08-20 2003-07-21 Us Gov Health & Human Serv Adenovirusmedieret overførsel af gener til mave-/tarmkanal
FR2688514A1 (fr) 1992-03-16 1993-09-17 Centre Nat Rech Scient Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
GB9223084D0 (en) 1992-11-04 1992-12-16 Imp Cancer Res Tech Compounds to target cells
DK0931830T3 (da) 1993-02-16 2001-06-11 Onyx Pharma Inc Cytopatiske vira til terapi og profylakse af neoplasi
FR2704234B1 (fr) 1993-04-22 1995-07-21 Centre Nat Rech Scient Virus recombinants, preparation et utilisation en therapie genique.
US5643900A (en) 1993-07-02 1997-07-01 Fotsis; Theodore Method for treatment of pathological conditions associated with angiogenesis and preparation therefor
FI951138L (fi) 1993-07-13 1995-04-13 Rhone Poulenc Rorer Sa Puuttellisia adenovirusvektoreita ja niiden käyttö geeniterapiassa
US5504074A (en) 1993-08-06 1996-04-02 Children's Medical Center Corporation Estrogenic compounds as anti-angiogenic agents
FR2712603B1 (fr) 1993-11-18 1996-02-09 Centre Nat Rech Scient Virus recombinants, préparation et utilisation en thérapie génique.
FR2712602B1 (fr) 1993-11-18 1996-02-09 Centre Nat Rech Scient Virus recombinants, préparation et utilisation en thérapie génique.
FR2716893B1 (fr) 1994-03-03 1996-04-12 Rhone Poulenc Rorer Sa Virus recombinants, leur préparation et leur utilisation thérapeutique.

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005530712A (ja) * 2002-03-20 2005-10-13 エラン ファーマ インターナショナル，リミティド 血管新生抑制剤のナノ粒子組成物
JP4842514B2 (ja) * 2002-03-20 2011-12-21 エラン ファーマ インターナショナル，リミティド 血管新生抑制剤のナノ粒子組成物

Also Published As

Publication number Publication date
ATE279212T1 (de) 2004-10-15
WO1998004291A1 (en) 1998-02-05
EP0921821A1 (en) 1999-06-16
AU723401B2 (en) 2000-08-24
AU3738397A (en) 1998-02-20
US20030099614A1 (en) 2003-05-29
DE69731213D1 (de) 2004-11-18
DE69731213T2 (de) 2006-02-23
EP0921821B1 (en) 2004-10-13
US6410029B1 (en) 2002-06-25
US5958892A (en) 1999-09-28
CA2262533A1 (en) 1998-02-05

Similar Documents

Publication Publication Date Title
JP2000517299A (ja) 癌細胞における２―メトキシエストラジオール誘導アポトーシス
US6977244B2 (en) Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides
Hermeking The MYC oncogene as a cancer drug target
Pietenpol et al. Paradoxical inhibition of solid tumor cell growth by bcl2
AU724212B2 (en) Down-regulation of DNA repair to enhance sensitivity to P53-mediated suppression
JP2000501394A (ja) ガンの診断および処置のための方法および組成物
JPH11510380A (ja) ｐ１６発現構築物および癌治療におけるその適用
US20060052322A1 (en) Combination treatment of cancer with elicitor of gene product expression and gene-product targeting agent
US6271207B1 (en) Enhanced expression of transgenes
US7105656B2 (en) Compositions and methods for treating hematologic malignancies and multiple drug resistance
US7704962B1 (en) Small oligonucleotides with anti-tumor activity
US20040043950A1 (en) WT1 antisense oligos for the inhibition of breast cancer
US20040101916A1 (en) Treatment of liver diseases
CA2557326A1 (en) Combination of ad-p53 and chemotherapy for the treatment of tumours
JP4280878B2 (ja) Ｍａｓｌ１遺伝子
AU2003202210A1 (en) WT1 antisense oligos for the inhibition of breast cancer
WO2000055344A1 (en) Adenoviral vector expressing a sv40 t antigen antisense rna
WO2013036636A1 (en) Compositions and methods of treating cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20040720

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20040720

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20070724

A313 Final decision of rejection without a dissenting response from the applicant

Free format text: JAPANESE INTERMEDIATE CODE: A313

Effective date: 20071219

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20080129